ALB vs LYB

The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of just 2/9, indicating significant deterioration in fundamental performance. Despite a strong recent price run-up (+115.4% over 1Y), the company is unprofitable (negative profit and operating margins), has negative earnings growth (YoY), and trades at an extremely high forward P/E of 82.85. While the balance sheet shows a healthy current ratio and manageable debt/equity of 0.37, the lack of Altman Z-Score and Graham Number, combined with deteriorating profitability and insider selling, raises serious concerns about sustainability. The analyst target price of $165.06 implies 13% downside from current levels, reinforcing overvaluation relative to fundamentals.

LYB exhibits severe fundamental deterioration, highlighted by a weak Piotroski F-Score of 2/9 and a critical dividend payout ratio of 1146.81%. While the stock has seen a recent price rally, the underlying financials show negative profit margins, negative ROE, and contracting revenue growth (-25.33% Q/Q). The combination of bearish insider sentiment and a 0/100 technical trend suggests the current price is unsupported by operational reality. The company is currently operating as a dividend trap, paying out far more than it earns.